Cerebral
Cerebral is an online mental health platform offering therapy, psychiatry, and medication management through a subscription-based telehealth model. The service connects patients with licensed therapists and prescribers for conditions including anxiety, depression, insomnia, and ADHD.
Score generated by AI agents based on publicly cited evidence and reviewed by the project maintainer. Not independently validated. Last assessed 2026-09-27. Score revised 2026-09-27: 56 → 40.
Score History
Timeline events are AI-curated from public reporting. Score trajectory is derived from documented events.
Cerebral launched in January 2020 as a subscription telehealth service for anxiety, depression and ADHD, just as COVID-19 cut off in-person care. Its care was basic but in demand. The subscription was hard to leave from the start: an easier cancel button added in April 2020 was pulled after two weeks at the CEO's direction when cancellations rose. Ad-platform tracking pixels had been on its website since October 2019.
From May 2021 Cerebral steered clinicians with undisclosed prescribing metrics tied to retention, later setting a 100% stimulant target for ADHD patients. It raised $127 million in June and $300 million in December at a $4.8 billion valuation. That summer it moved more than 200 clinicians from salaries to hourly pay and made their benefits depend on hours worked. Aggressive advertising, including ADHD ads that Meta and TikTok pulled in January 2022, fed patient acquisition while cancellation obstruction and pixel data-sharing continued.
A DOJ grand jury subpoena on May 4, 2022, following WSJ reporting and a former VP's whistleblower suit, ended the growth phase. Cerebral halted controlled-substance prescribing, the board removed founder-CEO Kyle Robertson, the FTC opened a probe into its subscription billing, and Aetna and Optum dropped it from their networks. Layoffs in June 2022, October 2022 (more than 1,000 people, including about 400 of 500 care counselors) and February 2023 followed, and the company sued Robertson over an unpaid $50 million share loan.
On March 6, 2023 Cerebral disclosed that tracking pixels had shared the health data of 3,179,835 people with Facebook, Google, TikTok and others since October 2019, and class actions followed within days. The company was smaller and had stopped prescribing controlled substances, but investigations by the FTC, DOJ and state regulators were all still open. In December 2023 the New York Attorney General's $740,000 settlement exposed slow-walked cancellations and instructions to staff to post fake reviews.
The FTC/DOJ order of April 15, 2024 required more than $7 million, including $5.1 million in refunds and $2 million of a $10 million penalty suspended for inability to pay. It also imposed a first-of-its-kind ban on using health data for most advertising and required an easy cancellation method. In November 2024 a non-prosecution agreement over the prescribing scheme added a $3.65 million forfeiture, with a further $2.9 million deferred. Settlements replaced investigations, but the company was financially fragile.
CEO David Mou stepped down in December 2024, and interim CEO Brian Reinken, a former board member, refocused the company on insurance-based care under a strategy he calls 'Cerebral 2.0'. FTC refunds went out in May 2025. The company bought clinician-training provider Resilience Lab in August 2025, raised $25 million and bought ADHD app Inflow in March 2026 to re-enter ADHD care without stimulants. User ratings have recovered, but surprise-charge complaints, provider turnover and permanently reduced services remain.
Alternatives
Nonprofit therapist directory offering reduced-cost sessions ($40-70 per individual session, $30 with student interns) from licensed providers after a one-time $65 membership fee — a non-corporate alternative for people who don't need psychiatric medication management. No recurring subscription, no upsells. Moderate switch — you're finding a therapist directly rather than using a managed platform, which requires more upfront research but avoids platform data practices entirely.
Online therapy platform with psychiatry and medication management, a direct alternative to Cerebral's core services without Cerebral's record of DOJ prescribing penalties, FTC data-sharing violations and high-pressure prescribing. Moderate switch: you'll need to transfer or restart your care relationship.
Dimensional Breakdown
Summaries below were written by AI agents based on the cited evidence. They are editorial interpretations, not independent research findings.
Dimension History
Timeline (45 events)
Cerebral founded by Kyle Robertson and Ho Anh
Kyle Robertson and Dr. Ho Anh, a former medical director at telehealth company Hims, co-founded Cerebral as an online mental health subscription service. The company launched at the onset of the COVID-19 pandemic, positioning itself to capitalize on surging demand for remote mental healthcare.
Cerebral pulls easy cancel button after two weeks
According to the FTC's complaint, when Cerebral first added an easier cancellation button in April 2020 it removed it after only two weeks, at CEO Kyle Robertson's direction, after cancellations rose. Customers were left with a complex, multi-step and often multi-day cancellation process despite 'cancel anytime' promises. The FTC cited this in its 2024 ROSCA charges.
Cerebral raises $35M Series A led by Oak HC/FT
Cerebral raised $35 million in Series A funding led by Oak HC/FT, with participation from WestCap, Liquid 2 Ventures, Gaingels and Air Angels. The funds were directed toward expanding to all 50 states, building a mobile app, and securing in-network insurance partnerships.
Cerebral implements prescribing metrics to boost stimulant prescriptions
From May 2021, Cerebral implemented internal metrics tracking the Initial Visit Rx Rate with a target of 95% and began tracking stimulant prescribing rates for ADHD patients. The company paid providers an additional $10 per prescription-related PDMP database check as a financial incentive. These metrics were not clinically justified and prioritized revenue retention over patient safety.
Cerebral failed to block former employees from accessing patient records
From May to December 2021, Cerebral failed to revoke former employees' access to confidential electronic medical records, allowing unauthorized access to sensitive patient data including diagnoses, medications, and contact information. The FTC later cited this as evidence of the company's failure to implement adequate security guardrails.
Cerebral raises $127M Series B, reaches $1.2B unicorn valuation
Cerebral raised $127 million in Series B funding led by Access Industries (Len Blavatnik), with participation from Silver Lake Waterman, Artis Ventures, and Bill Ackman. The round pushed Cerebral's valuation to $1.23 billion, making it a unicorn less than 18 months after founding. Funds were earmarked for expanding into group therapy, couples counseling, and new treatment areas.
Cerebral moves 200+ clinicians from salaries to hourly pay
In summer 2021 Cerebral moved more than 200 W-2 clinicians and other employees from salaried to hourly pay, Forbes reported. The clinicians lost guaranteed health benefits, which now required logging 30 hours of work a week for 90 days. The change drew criticism across the virtual mental health industry.
Cerebral sets ADHD stimulant prescribing target to 100%
From around October 2021, Cerebral instituted an internal plan to increase its ADHD Stimulant Rx Metric to 100% for patients without comorbidities, a plan that included auditing individual providers' ADHD prescribing and considering disciplinary measures, according to the U.S. Attorney's Office. A former VP's April 2022 lawsuit separately alleged that the chief medical officer told employees the goal was to prescribe stimulants to 100% of Cerebral's ADHD patients.
Simone Biles joins Cerebral as Chief Impact Officer
Olympic gold medalist Simone Biles partnered with Cerebral as Chief Impact Officer, three months after withdrawing from individual competition at the Tokyo Olympics to protect her mental health. The strategic partnership included financial commitments to providing mental health services in underserved communities and Cerebral's sponsorship of the Gold Over America Tour.
SoftBank leads $300M Series C at $4.8B valuation
Cerebral closed a $300 million Series C round led by SoftBank Vision Fund 2, with Prysm Capital, Access Industries, and WestCap Group participating. The valuation quadrupled to $4.8 billion, bringing total funding to $462 million. The company announced plans for international expansion and M&A to become a 'one-stop shop for behavioral care.'
Instagram and TikTok pull Cerebral ADHD ads for misleading health claims
Meta and TikTok removed Cerebral advertisements after NBC News inquiries revealed the ads linked ADHD to obesity with images of junk food, stating obesity is 'five times more prevalent' among adults with ADHD. The ads were found to violate platform policies against promoting misleading health claims and generating negative self-perception to sell health products.
Cerebral announces plans to hire 500 additional employees
At its peak, Cerebral announced plans to hire 500 new full-time employees by the end of 2022 to support its more than 420,000 customers. The workforce had grown from 5 employees at its January 2020 founding to over 1,000. Within months, the company would reverse course and begin three rounds of layoffs between mid-2022 and February 2023.
Wall Street Journal reports nurse practitioners felt pressured to prescribe stimulants
The Wall Street Journal reported that some clinicians at Cerebral and Done felt pressured to prescribe Adderall and other ADHD stimulants, saying the company's 30-minute patient evaluations were not long enough to properly diagnose ADHD. Some of the largest pharmacies also blocked or delayed prescriptions from these startups' clinicians.
Cerebral plans to offshore care coordinators at $8/hour
Business Insider reported that Cerebral planned to have 70% of its care coordinators based in the Philippines by June 2022, hired through the contractor ResolvedCX at $8 an hour. US-based coordinators usually started at $20 an hour. Care coordinators are the patients' front-line contact.
Former VP Matthew Truebe files whistleblower lawsuit alleging overprescribing
Matthew Truebe, former VP of product and engineering, filed a labor lawsuit claiming Cerebral fired him after he raised concerns about overprescription. He alleged the company aimed to prescribe stimulants to 100% of ADHD patients for retention purposes, found over 2,000 duplicate shipping addresses suggesting prescription fraud, and was retaliated against with a negative performance evaluation and stock option cuts.
DOJ serves grand jury subpoena for controlled substances investigation
Cerebral received a grand jury subpoena from the U.S. Attorney's Office for the Eastern District of New York relating to possible violations of the Controlled Substances Act. According to Insider, the subpoena sought documents including Cerebral's policies and procedures on controlled substances and records of its relationship with online pharmacy Truepill.
Cerebral pauses new controlled substance prescriptions for ADHD
On the same day it received the DOJ subpoena, Cerebral told clinicians to pause new prescriptions of controlled substances for ADHD, such as Adderall and Ritalin, for new patients effective May 9. Existing patients continued to receive their medications at that point; the company called it a pause.
Media Matters finds Cerebral spent $5M+ on Instagram ads in 2022
Media Matters reported that Cerebral spent more than $5 million on Instagram advertising since the beginning of 2022, earning over 630 million impressions according to Pathmatics. Despite having reportedly paused prescribing controlled substances, the company continued running Instagram ads for ADHD diagnoses and other services.
CEO Kyle Robertson terminated, David Mou named replacement
Cerebral's board of directors removed founder and CEO Kyle Robertson amid the DOJ investigation and prescribing controversy; Chief Medical Officer and President David Mou was named CEO. Robertson fired back in a memo to the board, calling the move illegal and saying directors were trying to make him a scapegoat and had encouraged the company to prescribe Adderall.
Cerebral stops prescribing all controlled substances
Cerebral announced it would stop prescribing most controlled substances, including stimulants like Adderall and benzodiazepines like Xanax. New patients were cut off from May 20; existing patients had to transition off or transfer care by October 15. The company continued prescribing only medications for opioid use disorder. This eliminated a core value proposition for ADHD patients.
First round of layoffs announced amid DOJ investigation
Cerebral announced its first round of layoffs effective July 1, citing a focus on quality and operational efficiency. The company did not disclose specific numbers. This came just weeks after the CEO ouster and DOJ subpoena, marking the beginning of three rounds of layoffs through February 2023.
FTC opens probe into Cerebral subscription billing
The Wall Street Journal reported that the FTC had sent Cerebral a letter opening an investigation into possible deceptive or unfair advertising and marketing, including its negative-option subscription billing and cancellation processes. Patients had reported trouble closing accounts and getting refunds. The same reporting said Aetna and UnitedHealth's Optum had removed Cerebral from their networks.
CBS News investigation reveals staff practiced with expired licenses
CBS News reported that documents showed Cerebral leadership was informed about staff practicing with expired or suspended licenses, patient safety issues, and hires who did not meet company standards. An internal log showed nearly 1,200 instances of prescribers being unresponsive to patients over 11 months. Some patients received prescriptions and were then unable to reach their prescriber for safety instructions.
Cerebral lays off 20% of workforce, over 1,000 employees
Cerebral announced its second and largest round of layoffs, cutting 20% of its workforce or more than 1,000 employees from a headcount of approximately 5,500. Roughly 400 of 500 care counselors were eliminated. CEO David Mou stated the cuts were made to 'best serve our clients,' but the scale reflected post-pandemic demand contraction and the loss of the controlled substance prescribing business.
Cerebral sues ousted CEO Kyle Robertson over unpaid $50M loan
Cerebral filed a lawsuit in New York Supreme Court alleging founder Kyle Robertson defaulted on a nearly $50 million loan taken in January 2022 to purchase 1.06 million shares of company stock. Robertson owed 51% of the principal ($25.4 million) plus interest, which was due within six months of his May termination. Robertson allegedly refused to repay despite his contractual obligation.
DEA serves order to show cause against pharmacy partner Truepill
The DEA issued an Order to Show Cause against Truepill, Cerebral's pharmacy fulfillment partner, for unlawfully dispensing controlled substance prescriptions. Between September 2020 and September 2022, Truepill filled over 72,000 controlled substance prescriptions, 60% of which were stimulants. The DEA found prescriptions that exceeded supply limits and were written by prescribers lacking proper state licensing.
Simone Biles ends partnership with Cerebral
Simone Biles's endorsement contract with Cerebral ended and was not extended, ending her role as Chief Impact Officer, the Wall Street Journal reported. The split came seven months after the DOJ investigation surfaced and amid ongoing prescribing controversies. According to a board memo obtained by the WSJ, then-CEO Robertson had pressed for Biles to align her messaging with the company's 'core value prop (eg meds, ADHD)'.
Cerebral closes MAT program and lays off 15% of remaining staff
Cerebral quietly closed its medication-assisted treatment program for opioid use disorder, transitioning fewer than 20 remaining OUD patients to alternative care. On the same day it announced layoffs of more than 250 employees, about 15% of its workforce. This was the third round of layoffs in less than a year.
Cerebral discloses 3.1M patient data breach from tracking pixels
Cerebral filed a breach notification with HHS and sent letters to users acknowledging that tracking pixels on its website and apps had shared personal health information of 3,179,835 patients with Facebook, Google, TikTok, and other third parties since October 2019. Exposed data included names, birthdates, IP addresses, mental health self-assessments, insurance details, and treatment information.
Class action lawsuit filed over tracking pixel data breach
A proposed class action was filed in federal court alleging Cerebral violated federal and California privacy laws by sharing patient data with Facebook, Google, TikTok and other platforms through embedded tracking pixels. The suit cited Cerebral's disclosure that the private information of at least three million people was improperly shared without consent.
NY Attorney General secures $740,000 for deceptive cancellation practices
New York Attorney General Letitia James secured more than $740,000 from Cerebral, including $540,162 in restitution to 16,552 consumers and $200,000 in penalties. The investigation found Cerebral required email-based cancellations with additional steps and up to a week's delay, charged consumers when delays crossed billing dates, and instructed employees to post fake positive reviews and suppress negative ones.
FTC imposes $7M settlement and permanent health data advertising ban
The DOJ, on referral from the FTC, filed a proposed settlement requiring Cerebral to pay more than $7 million: nearly $5.1 million for partial consumer refunds plus $2 million of a $10 million civil penalty, the rest suspended due to inability to pay. The complaint alleged Cerebral shared nearly 3.2 million consumers' health data with third parties for advertising and misled consumers about cancellation. The order included a first-of-its-kind ban on using health information for most advertising purposes, a website notice, and a data retention and deletion requirement. The FTC also alleged Cerebral sent promotional postcards without envelopes to 6,000+ patients, revealing diagnoses.
Cerebral reveals inability to pay full $10M FTC civil penalty
Court filings revealed Cerebral could not afford to pay the full $10 million civil penalty, which was suspended after a $2 million payment. Combined with the $5.1 million in consumer refunds and other settlement costs, the financial fragility exposed how the VC-funded growth-at-all-costs model left the company hollowed out despite raising $462 million in total funding.
DOJ adds founder's new company Zealthy to FTC complaint
The DOJ and FTC announced an amended complaint adding Zealthy Inc. (later renamed Gronk Inc.), founded by ex-Cerebral CEO Kyle Robertson, its affiliate Bruno Health and executive German Echeverry to the existing case against Robertson. The government alleged Robertson continued violating the FTC Act and ROSCA at Zealthy: failing to disclose subscription terms before taking billing information, charging cards without informed consent, and failing to provide a simple cancellation process.
DOJ/DEA levies $3.6M fine for pushing controlled substance prescriptions
Cerebral entered a non-prosecution agreement with the U.S. Attorney's Office for the Eastern District of New York, paying $3,652,000 in forfeiture for exploiting telehealth flexibilities to boost stimulant prescriptions. An additional $2,922,000 penalty was deferred due to inability to pay. The DOJ documented that Cerebral used financial incentives and considered disciplinary measures to pressure providers into meeting prescribing metrics from 2021 to 2022.
CEO David Mou steps down; Reinken becomes interim CEO
David Mou stepped down as CEO in December 2024 and founded AdvocateMH, a behavioral health triage startup. Former board member Brian Reinken became interim CEO and president, and the company said it was increasing its focus on insurance-based care. Mou continued as chief medical officer in an advisory role. Reinken is Cerebral's third CEO since its 2020 founding.
FTC distributes $5.1M in refunds to 40,249 consumers
The FTC announced that independent administrator Epiq Systems was distributing $5.1 million in refunds to 40,249 consumers who were charged after requesting subscription cancellation. Payments covered consumers who submitted cancellation requests on or before May 2022 but were billed anyway. Most received checks; those without addresses on file received PayPal payments.
Cerebral makes first acquisition, buying Resilience Lab
Cerebral acquired Resilience Lab, a behavioral health organization focused on clinician training and outcomes-focused care delivery. The acquisition brought Resilience Lab's proprietary clinical development platform, designed to reduce therapist turnover and burnout. The combined organization serves more than 100 million commercial insurance members under the Cerebral brand.
California class action pixel data breach settles for $500,000
Cerebral agreed to a $500,000 class action settlement, preliminarily approved on August 26, 2025, to resolve a lawsuit over Meta pixel data sharing. The settlement covers California accountholders who received data breach notification letters in March 2023. Class members who file valid claims are eligible for a pro rata cash payment and a $300 credit toward Cerebral self-pay services, pending final approval.
Cerebral raises $25M in new capital following Resilience Lab acquisition
Cerebral raised $25 million in capital approximately one month after its Resilience Lab acquisition, bringing total funding to roughly $487 million. The raise signaled continued investor confidence in the recovery strategy and funded the integration of Resilience Lab's clinician training infrastructure into Cerebral's platform.
HelpGuide survey finds widespread surprise charges at Cerebral
HelpGuide surveyed more than 200 Cerebral users in May 2025 and tested the service hands-on. 33% of therapy users and 19% of psychiatry users reported surprise charges. The tester found self-pay prices confusing and inconsistent across pages, was matched only with associate-level therapists without clear disclosure, and got automated replies to medication questions. Overall satisfaction was high: 90% of therapy users and 94% of psychiatry users were satisfied.
Cerebral Institute opens proprietary training to external partner
Cerebral opened its Cerebral Institute clinician training program to its first external partner, Williamsburg Therapy Group, integrating it into WTG's post-doctoral fellowship program. The Institute, built on Resilience Lab's methodology, reports an 80% licensure rate for its provisionally licensed therapists versus a national average of about 54%. The external partnership signaled a pivot toward quality-focused revenue generation.
Cerebral acquires ADHD app Inflow, re-entering ADHD care
Cerebral acquired Inflow, a CBT-based ADHD skills app that raised $11 million in 2023. It is Cerebral's second acquisition ever. CEO Brian Reinken said the company still does not prescribe controlled substances but offers non-stimulant medications, and that Inflow will run separately for now as a between-session support tool.
DOJ seeks Zealthy receivership citing Robertson's Cerebral conduct
The DOJ filed an amended complaint and moved to freeze the assets of Zealthy, the telehealth company founded by ex-Cerebral CEO Kyle Robertson, and to place it in receivership. The filing alleged that Robertson had broken the law at both Cerebral and Zealthy, including unauthorized charges, deliberately obstructed cancellations and thousands of fake reviews. Cerebral, which settled in 2024, is not named in the amended suit.
Court grants final approval to $500K Cerebral pixel settlement
The San Francisco Superior Court granted final approval to Cerebral's $500,000 settlement of the Doe v. Cerebral class action over Meta pixel data sharing, which covers California accountholders notified in March 2023. After fees about $267,000 was left for cash payments, and class members could also claim a $300 credit toward self-pay care. Payments went out on June 22, 2026.
Evidence (54 citations)
D1: User Value Erosion
D2: Business Customer Exploitation
D3: Shareholder Extraction
D4: Lock-in & Switching Costs
D5: Twiddling & Algorithmic Opacity
D6: Dark Patterns
D7: Advertising & Monetization Pressure
D8: Competitive Conduct
D9: Labor & Governance
D10: Regulatory & Legal Posture
Scoring Log (9 entries)
Checked 86 items + prose. 47 verified, 25 corrected (7 date-only), 12 re-sourced, 2 removed (1 duplicate, 1 unsupported). Invented/contradicted: Android app rating '2.9/5' (Choosing Therapy: 4.4 on Google Play); provider benefits threshold '35 hours' and 'per-service to hourly' (Forbes 2021-12-16: salaried to hourly, benefits need 30+ hrs/week, summer 2021); 'total regulatory penalties exceeded $12M' (FTC ~$7.1M + DOJ $3.65M + NY AG $0.74M = ~$11.5M). Also fixed FTC '$7M fine reduced from $15M' framing and double counting of refunds, Truepill '72,000 problematic prescriptions', Zealthy date (June 2024, not Sept), 'four rounds'/'35%' layoffs (three rounds documented), BetterHelp 9.8% share, and 92% Institute engagement. [Amended by regrade 2026-09-27: timeline[23] still said layoffs brought 'total workforce reductions to roughly 35%', which the fact audit found unsupported and removed from other items; removed the clause and set the headcount to 'more than 250' per BHB 2023-02-27. timeline[31] title still said 'third CEO transition' after the fact audit corrected it to two changes, and its description said 'third CEO since 2022'; retitled and fixed to 'third CEO since its 2020 founding'.]
Since Feb 2026: Cerebral bought ADHD app Inflow (Mar 2026), the $500K pixel class settlement received final approval (May 5, 2026), the DOJ sought a receivership of Robertson's Zealthy (Apr 2026, Cerebral not named) and no new enforcement against Cerebral surfaced; CEO Reinken is running the 'Cerebral 2.0' insurance pivot. The 'Eric Randall CEO' lead is unverified (only LinkedIn/Tracxn; BHB Jul 2026 still names Reinken). 56→40. D1 6→5 (event: post-2024 recovery, ratings 4.4-4.6, clinician-quality acquisitions; controlled substances still gone). D2 5→4 (recalibration: no clinician-exploiting policy change since 2022; hourly/session pay persists). D3 6→4 (recalibration: no buybacks or dividends; growth-at-all-costs era scored in past eras; the company now reinvests). D4 5→3 (recalibration: no network effects, many competitors, HIPAA access; FTC order requires easy cancel and data deletion). D6 8→5 (recalibration: the 2020-22 roach motel is scored in past eras; now an order-bound easy cancel, but 33% of therapy users report surprise charges). D7 5→3 (recalibration: no ads; health-data advertising stopped Jan 2023 and banned 2024). D8 3→2 (recalibration: two small capability acquisitions). D9 7→5 (recalibration: layoffs and whistleblower case are 2022-23 facts; no layoffs since; poor Glassdoor). D10 7→5 (recalibration: serial settlements but no lobbying or litigation against regulators; no new actions since 2024). D5 unchanged at 4. Eras: 'Pandemic Launch' kept (re-scored; D6 raised to 6 after finding the Apr 2020 cancel-button removal); 'VC Hypergrowth' re-dated 2021-12-01→2021-05-01 (prescribing metrics); 'Prescribing Scandal' re-dated 2022-05-01→2022-05-04 (DOJ subpoena); 'Data Breach Fallout' re-dated 2023-03-01→2023-03-06 (HHS disclosure); 'Enforcement Settlements' re-dated 2024-04-01→2024-04-15 (FTC order); current era re-dated 2026-02-16→2024-12-01 (Mou exit and insurance pivot) and relabeled 'Regulatory Reform'→'Cerebral 2.0 Rebuild'. Added historical events: Apr 2020 cancel-button removal, summer 2021 hourly-pay switch, Mar 2022 offshore coordinators, Jun 2022 FTC probe. Flag: HelpGuide says prescriber messages are visible to other staff (not scored).
Checked 8 removed/trimmed claims: 1 restored, 0 partly restored, 7 confirmed removed, 0 already present. RESTORED (as new D10 evidence item, since the timeline item's Fierce URL does not carry it): subpoena sought documents dating back to the 2020 launch, including controlled-substance policies, financials and procedures to root out prescription fraud (MobiHealthNews 2022-05-09, citing Insider). CONFIRMED REMOVED: ~35% total headcount reduction (only 20% Oct 2022 and 15% Feb 2023 rounds documented; no source states 35%); WSJ 'prescribe first and evaluate later' (Fierce reports of WSJ story lack it; not found in searches); Cerebral Institute '92% client engagement' (Business Wire blocked; not found in searches or Cerebral/Resilience Lab pages); BetterHelp 9.8% share (not on cited page or in searches); Glassdoor 38% recommend and 2.9/5 (no archive; current Glassdoor listings show 26%).
Removed typed-in site scores from alternatives text (they go stale on re-score; the page shows live scores). No other changes.
Triaged 2026-06-30 (Wave A); no rescore warranted (no material change / changes sub-threshold / flag refuted on verification).
Added 1 missing dimension narrative